The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
if the tumor um is estrogen or are positive we go through a process where we decide whether or not the patient needs chemotherapy and that usually involves um an oncotype DX recurrent score or similar genomic test done on the tumor itself where they look at the patterns of gene expression in the tumor
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
so the good news is we are able to figure out a lot of women don't actually need chemotherapy for ER positive her2 negative breast cancers there's this genomic test we get to help us decide whether chemotherapy is going to be valuable and with that about 2third of the women who were previously offered chemotherapy can now avoid chemotherapy
those have been shown to be very powerful at figuring out who does and more importantly who does not need chemotherapy so there's been a huge shift in how we use chemotherapy in ER positive breast cancers over the past 25 years from the time in 1999 when the NCI said every woman who had a 1 cimeter cancer needed chemotherapy to a Time nowadays when we frequently can avoid chemotherapy for most ER positive breast cancers certainly those that are noed negative and many of the ones that are noed positive as well because we understand that based on this genomic test the chemotherapy is just not going to help them do better in the long run
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.